CytoDyn is a publicly traded biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses. CytoDyn s lead product candidate, PRO , has the potential to drive groundbreaking advancements in developing the next generation of HIV treatments.
Quote | CytoDyn Inc (OTCMKTS:CYDY)
Last: | $0.135 |
---|---|
Change Percent: | -0.55% |
Open: | $0.134 |
Close: | $0.13575 |
High: | $0.139 |
Low: | $0.134 |
Volume: | 460,222 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | CytoDyn Inc (OTCMKTS:CYDY)
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...
Message Board Posts | CytoDyn Inc (OTCMKTS:CYDY)
Subject | By | Source | When |
---|---|---|---|
dfwl28: "A causal role was recently attributed to inflammation in many malignant diseases, including | dfwl28 | investorshangout | 05/06/2023 2:14:07 PM |
Hulk767: reading these articles / reports reminds me of how great it will be to get coverage by a re | Hulk767 | investorshangout | 05/06/2023 2:14:00 PM |
dfwl28: "Tumor cells can hijack chemokine networks to support tumor progression. In this context, th | dfwl28 | investorshangout | 05/06/2023 1:42:49 PM |
seemingly-harmless: yes the billing code revelation took a good tug at my wallet also....if they wer | seemingly-harmless | investorshangout | 05/06/2023 1:25:50 AM |
AngryMan: All we can do is hope it is soon. ER thanks for keeping this board as a credible place. I | AngryMan | investorshangout | 05/05/2023 8:05:34 PM |
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...
VANCOUVER, Washington, May 16, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024 fiscal year (May 31, 2024), and to sincerely thank you for your unwavering...